Press Releases
Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced the closing of a $16 million Series B financing. The...
Press Releases
Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health...
News
Gilead’s Investigational Antiviral Veklury Receives U.S. FDA Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
Gilead Sciences, Inc. announced the U.S. FDA expanded the EUA enabling use of the investigational antiviral Veklury® (remdesivir) to treat all hospitalized patients with...
News
Chiesi Group and JAGGAER Drive Strategic Supplier Management and Procurement Excellence
Chiesi Group, an international pharmaceutical corporation focused on research, development, and production of innovative medicines, has selected JAGGAER, the world’s largest independent spend management...
News
Bruker and Purity-IQ sign partnership agreement to transform the cannabis regulatory landscape
Bruker and Purity-IQ have joined forces to create a powerful new testing system for medical cannabis in Canada. The Purity-IQ Cannabis Fingerprint™ combines Bruker’s...
News
Novavax to Supply 76M Doses of COVID-19 Vax to Canada
Novavax, Inc. has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19...
News
FDA Clears SPI’s Ebselen for Phase II COVID-19 Trials
Sound Pharmaceuticals, Inc. (SPI) received clearance from the FDA to begin two Phase 2 studies of ebselen (SPI-1005) in COVID-19 patients. SPI-1005 is a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read